
CORRECTION





Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients

Wei Bai^{1†}, Fan Yang^{1†}, Huji Xu², Wei Wei³, Hongbin Li⁴, Liyun Zhang⁵, Yi Zhao⁶, Xiaofei Shi⁷, Yan Zhang⁸, Xiaofeng Zeng^{1*} and Xiaomei Leng^{1*}

Correction: BMC Trials 24, 112 (2023) https://doi.org/10.1186/s13063-023-07087-5

Following publication of the original article [1], we have been notified that affiliations 1 to 4 are actually different titles within the same department and should be gathered under just one affiliation.

Additionally, the following sentence was added in the Funding section: This study was supported by the National High Level Hospital Clinical Research Funding (2022-PUMCH-A-227).

The original article has been corrected.

[†]Wei Bai and Fan Yang contributed equally to this study.

The original article can be found online at https://doi.org/10.1186/s13063-023-07087-5

*Correspondence:

Xiaofeng Zeng xiaofeng.zeng@cstar.org.cn Xiaomei Leng lpumch@126.com

¹ Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China

Published online: 31 July 2023

Reference

Bai, et al. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients. BMC Trials. 2023;24:112. https://doi.org/10.1186/s13063-023-07087-5.

- ² Department of Rheumatology and Immunology, Changzheng Hospital, Naval Medical University, Shanghai 200003, China
- ³ Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, China
- ⁴ Department of Rheumatology, The Afliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China
- ⁵ Department of Rheumatology, Third Hospital of Shanxi Medical University, Bethune Hospital Shanxi Academy of Medical Sciences,
- Taiyuan, Shanxi, China ⁶ Department of Rheumatology and Allergy, Xuanwu Hospital, Capital
- Medical University, Beijing, China ⁷ Department of Rheumatology and Immunology, The First Afliated
- Hospital and College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China
- ⁸ Department of Rheumatology and Immunology, Tangdu Hospital, Fourth Military Medical University (Air Force Medical University), Xi'an, Shaanxi, China



© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data